Chemotherapy Decision-Making in Early Breast Cancer

Video

This video discusses chemotherapy decision-making in early-stage breast cancer, and reviews tools such as PREDICT 2.0 and the MammaPrint 70-gene assay that can help guide treatment.

In this video, N. Lynn Henry, MD, PhD, of the University of Utah Huntsman Cancer Institute, discusses chemotherapy decision-making in early-stage breast cancer, and reviews tools such as PREDICT 2.0 and the MammaPrint 70-gene assay that can help guide treatment.

Henry spoke on this topic at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held last month in Chicago.

Recent Videos
A machine learning method for scoring tumor-infiltrating lymphocytes may address variability in pathologist measurements.
Clinical trials in small cell lung cancer appear to be more “pragmatic” with their inclusion criteria than before, according to Anne Chiang, MD, PhD.
Related Content
The administration of proton beam therapy requires less specialized training but is also more expensive.

Proton Beam Therapy and IMRT Confer Similar AEs and QOL in Oropharyngeal Cancer

Ariana Pelosci
September 29th 2025
Article

Regarding feeding tube use and weight loss, patients with oropharyngeal cancer treated with proton beam therapy or IMRT saw similar results.

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

Gary Steinberg, MD
September 29th 2025
Podcast

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

T-DXd demonstrated a safety profile consistent with previously reported analyses.

T-DXd Improves Invasive DFS vs T-DM1 in HER2+ Early Breast Cancer Subgroup

Tim Cortese
September 29th 2025
Article

Planned interim results from the phase 3 DESTINY-Breast05 trial showed no new safety signals with T-DXd in the trial population.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Laser vision correction. A patient and team of surgeons in the operating room during ophthalmic surgery. Eyelid speculum. Lasik treatment.| Image Credit: © romaset-stock.adobe.com

Brachytherapy/Vitrectomy, Silicone Oil Confer Positive Uveal Melanoma DMFS

Ariana Pelosci
September 28th 2025
Article

An 80% disease metastasis-free survival rate occurred in those with uveal melanoma who received a brachytherapy plaque with vitrectomy and silicone oil.

Underscoring Genetic Testing’s Role in Enhancing Ovarian Cancer Care

Underscoring Genetic Testing’s Role in Enhancing Ovarian Cancer Care

Roman Fabbricatore
September 27th 2025
Article

Artificial intelligence can be used to automate genetic counseling processes and streamline a patient’s communication with relatives regarding genetic risk.